News

Podcast

Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations

Author(s):

Alexandra Gerlach, Associate Editor

Pharmacists discuss how drug design impacts drug efficacy and indications for HER2-low and -ultra-low breast cancer.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
5 experts in this video
Image credit: Sebastian Kaulitzki | stock.adobe.com
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue
5 experts in this video
5 experts in this video
Related Content
Doctor holding bladder model | Image Credit: © M+Isolation+Photo - stock.adobe.com
June 12th 2025

Mitomycin Intravesical Solution Receives FDA Approval for Non-Muscle Invasive Bladder Cancer

Alexandra Gerlach, Associate Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Oral herbal supplement -- Image credit: Vitalii Vodolazskyi | stock.adobe.com
June 12th 2025

You Shall Not Pass: Pharmacist Review of Drug-Herb Interactions in Cancer Treatment

Hanna Yakubi, PharmD Cody Angerman, PharmD Iris Zhao, PharmD, BCOP, BCPS, APh Saumya Papneja, PharmD, BCOP Christina Marengo, PharmD Mency Zhu, PharmD Ryan Beechinor, PharmD, BCPS, BCOP
New Programs Aim to Improve Implementation of Cardiovascular Interventions
June 3rd 2025

New Programs Aim to Improve Implementation of Cardiovascular Interventions

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
FDA Approves Tablet Formulation of Zanubrutinib for All Indications
June 11th 2025

FDA Approves Tablet Formulation of Zanubrutinib for All Indications

Luke Halpern, Assistant Editor
Hepatitis C virus model, 3D illustration. A virus consists of a protein coat, capsid, surrounding RNA and outer lipoprotein envelope with two types of glycoprotein spikes, E1 and E - Image credit: Dr_Microbe | stock.adobe.com
June 11th 2025

Glecaprevir/Pibrentasvir Combination Receives FDA Approval Expanded Indication for Acute HCV

Kennedy Ferruggia, Assistant Editor